Elthera AG

Elthera AG is a Swiss biopharmaceutical start-up company bringing together experienced pharma and biotech executives with cutting-edge academic researchers to develop proprietary, first-in-class oncology drugs using a personalized health care approach. Elthera AG is developing antibodies against a novel target whose expression is strongly correlated with an aggressive tumor phenotype and poor prognosis in various types of cancer. By combining targeted therapies with companion diagnostics, Elthera AG is aiming at providing new personalized treatment options for patients with the most aggressive malignancies.